Nuvectis Pharma, Inc. (NVCT) vs Verastem, Inc. (VSTM)

Nuvectis Pharma, Inc. and Verastem, Inc. are both Biotechnology companies. Nuvectis Pharma, Inc. and Verastem, Inc. are of similar size ($706.1M and $694.6M). Nuvectis Pharma, Inc. has the higher net margin (0.00% vs −231.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Nuvectis Pharma, Inc. leads on 7 and Verastem, Inc. on 5.

Valuation

Metric NVCT VSTM Biotechnology median
P/E n/m n/m 7.88
P/S n/m 8.89 11.47
P/B 52.27 15.56 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 8.29 10.73
Earnings yield (6.48%) (31.66%) (28.84%)
Free cash flow yield (4.11%) (20.85%) (23.03%)

Profitability

Metric NVCT VSTM Biotechnology median
Gross margin — 86.35% 65.16%
Operating margin 0.00% (182.57%) 0.00%
Net margin 0.00% (231.59%) 0.00%
Free cash flow margin 0.00% (185.31%) 0.00%
Return on equity (233.30%) (471.16%) (57.72%)
Return on assets (122.61%) (100.65%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NVCT VSTM Biotechnology median
Revenue growth (TTM) — 472.89% 5.64%
EPS growth (last fiscal year) (18.92%) 17.49% —
Revenue growth, 5-year CAGR — 12.11% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NVCT VSTM Biotechnology median
Debt to equity 0.00 1.48 0.00
Current ratio 1.68 2.25 4.73
Net debt to EBITDA 1.15 0.76 0.96

Dividend

Metric NVCT VSTM Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric NVCT VSTM Biotechnology median
Market cap 706.09m 694.62m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack